Published On: Wed, Oct 19th, 2016

Heron Therapeutics Inc (HRTX) Updated Broker Ratings


A number of investment brokers have recently updated their price targets on shares of Heron Therapeutics Inc (HRTX).

Most recent broker ratings

10/04/2016 – Brean Capital began new coverage on Heron Therapeutics Inc giving the company a “buy” rating. They now have a USD 41 price target on the stock.

10/03/2016 – Heron Therapeutics Inc had its “buy” rating reiterated by analysts at Jefferies. They now have a USD 40 price target on the stock.

10/03/2016 – Heron Therapeutics Inc had its “outperform” rating reiterated by analysts at Leerink Swann. They now have a USD 33 price target on the stock.

09/06/2016 – Lake Street began new coverage on Heron Therapeutics Inc giving the company a “buy” rating. They now have a USD 45 price target on the stock.

08/10/2016 – Heron Therapeutics Inc had its “buy” rating reiterated by analysts at Cantor Fitzgerald. They now have a USD 38 price target on the stock.

04/19/2016 – Heron Therapeutics Inc had its “outperform” rating reiterated by analysts at Cowen. They now have a USD 47 price target on the stock.

04/19/2016 – Heron Therapeutics Inc had its “buy” rating reiterated by analysts at Noble Financial. They now have a USD 51 price target on the stock.

09/23/2015 – Heron Therapeutics Inc had its “buy” rating reiterated by analysts at Bank of America Merrill Lynch. They now have a USD 54 price target on the stock.

09/23/2015 – Heron Therapeutics Inc had its “market outperform” rating reiterated by analysts at JMP Securities. They now have a USD 56 price target on the stock.

The share price of Heron Therapeutics Inc (HRTX) was down -1.91% during the last day of trading, with a day high of 15.95. 390499 shares were traded during the last session.

The stock’s 50 day moving average is 17.83 and its 200 day moving average is 18.80.Heron Therapeutics Inc has a 52-week low of 14.75 and a 52-week high of 31.32.

Heron Therapeutics, Inc. is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology. The Company’s SUSTOL (granisetron) injection, extended release is being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). HTX-019, which is an intravenous formulation of aprepitant, a neurokinin-1 (NK1) receptor antagonist, is being developed for the prevention of CINV. HTX-011, a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam, is being developed for the prevention of post-operative pain. HTX-011 is in Phase II clinical trials.